Medical Crossfire®: Expert Perspectives on c-MET and MET Targeting in NSCLC—Unveiling the Complexities of MET Dysregulation
Season 2, Episode 42, Jul 30, 01:30 PM
Share
Subscribe
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; and Jeremy Segal, MD, PhD, discuss the emerging data and clinical strategies for targeting c-MET overexpression and MET genomic alterations in non–small cell lung cancer (NSCLC), including the role of novel antibody-drug conjugates (ADCs), such as telisotuzumab vedotin (Teliso-V), combination approaches with EGFR-Tyrosine kinase inhibitors (TKIs), and optimal molecular testing practices for appropriate patient selection.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
In this podcast, experts Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; and Jeremy Segal, MD, PhD, discuss the emerging data and clinical strategies for targeting c-MET overexpression and MET genomic alterations in non–small cell lung cancer (NSCLC), including the role of novel antibody-drug conjugates (ADCs), such as telisotuzumab vedotin (Teliso-V), combination approaches with EGFR-Tyrosine kinase inhibitors (TKIs), and optimal molecular testing practices for appropriate patient selection.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify optimal molecular testing strategies for individual categories of MET dysregulation in patients with NSCLC along the continuum of care.
- Assess safety and efficacy results from clinical trials investigating MET-targeted approaches for the management of patients with advanced NSCLC.
- Analyze ongoing trials and emerging data for novel strategies targeting c-MET overexpression in patients with NSCLC with or without EGFR mutations.
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from AbbVie, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from AbbVie, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 6732
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 6732
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Chair:
Rebecca Heist, MD, MPH
Professor of Medicine
Harvard Medical School
Thoracic Oncology, MGH Cancer
Massachusetts General Hospital
Boston, MA
Disclosures: Consultant: Amgen, AstraZeneca, Biohaven, Claim, Daiichi Sankyo, Gilead, Lilly, Merck
Faculty:
Alex A. Adjei, MD, PhD, FACP
Chief, Cancer Institute
Director, Taussig Cancer Center
M. Frank Rudy and Margaret D. Rudy Distinguished Chair in
Translational Cancer Research
Cleveland Clinic
Cleveland, OH
Alex A. Adjei, MD, PhD, FACP, has no relevant financial relationships with ineligible companies.
Chair:
Rebecca Heist, MD, MPH
Professor of Medicine
Harvard Medical School
Thoracic Oncology, MGH Cancer
Massachusetts General Hospital
Boston, MA
Disclosures: Consultant: Amgen, AstraZeneca, Biohaven, Claim, Daiichi Sankyo, Gilead, Lilly, Merck
Faculty:
Alex A. Adjei, MD, PhD, FACP
Chief, Cancer Institute
Director, Taussig Cancer Center
M. Frank Rudy and Margaret D. Rudy Distinguished Chair in
Translational Cancer Research
Cleveland Clinic
Cleveland, OH
Alex A. Adjei, MD, PhD, FACP, has no relevant financial relationships with ineligible companies.
Sandip Patel, MD, FASCO
Professor, Medical Oncology
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Experimental Therapeutics Program
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
University of California San Diego
San Diego, CA
Disclosures: Institutional Research Funding:A2 Bio, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech; Scientific Advisory Board: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Eli Lilly, Genentech, Illumina, Jazz, Merck, Pfizer
Jeremy Segal, MD, PhD
Vice Chair, Genomic Pathology
Professor of Pathology
University of Chicago
Chicago, IL
Disclosures: Adviser: AstraZeneca, Bristol Myers Squibb, OrisDX; Equity Recipient: OrisDX; Honoraria Recipient: AstraZeneca, Bristol Myers Squibb, Roche Diagnostics; Speaker: Roche Diagnostics
Professor, Medical Oncology
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Experimental Therapeutics Program
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
University of California San Diego
San Diego, CA
Disclosures: Institutional Research Funding:A2 Bio, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech; Scientific Advisory Board: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Eli Lilly, Genentech, Illumina, Jazz, Merck, Pfizer
Jeremy Segal, MD, PhD
Vice Chair, Genomic Pathology
Professor of Pathology
University of Chicago
Chicago, IL
Disclosures: Adviser: AstraZeneca, Bristol Myers Squibb, OrisDX; Equity Recipient: OrisDX; Honoraria Recipient: AstraZeneca, Bristol Myers Squibb, Roche Diagnostics; Speaker: Roche Diagnostics
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on biomarker-driven management of patients with EGFR-mutated non–small cell lung cancer (NSCLC), go to http://gotoper.com/annual-oncology-meeting-25-cmet-activity.
Release Date
July 30, 2025
Expiration Date
July 30, 2026
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.